Philadelphia, PENNSYLVANIA2 Active Studies

Huntingtons Disease Clinical Trials in Philadelphia, PENNSYLVANIA

Find 2 actively recruiting huntingtons disease clinical trials in Philadelphia, PENNSYLVANIA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
650
Enrolling

Recruiting Huntingtons Disease Studies in Philadelphia

About Huntingtons Disease Clinical Trials in Philadelphia

Huntington's disease is an inherited condition that causes progressive degeneration of nerve cells in the brain, affecting movement, cognition, and behavior. It is caused by a mutation in the HTT gene. Current treatments manage symptoms, while gene-silencing therapies are being studied.

There are currently 2 huntingtons disease clinical trials recruiting participants in Philadelphia, PENNSYLVANIA. These studies are seeking a combined 650 participants. Research is being sponsored by Daniel Coury, University of Pennsylvania. Clinical trial participation is free and participants receive study-related medical care at no cost.

Huntingtons Disease Clinical Trials in Philadelphia — FAQ

Are there huntingtons disease clinical trials in Philadelphia?

Yes, there are 2 huntingtons disease clinical trials currently recruiting in Philadelphia, PENNSYLVANIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What huntingtons disease treatments are being tested?

The 2 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for huntingtons disease.

Data updated March 2, 2026 from ClinicalTrials.gov